Translarna

Indicated For

nonsense mutation Duchenne muscular dystrophy

About This Medication

# Translarna (Ataluren) Patient Guide: How to Get Translarna (Ataluren) at Low or No Cost **Important Notice**: As of February 2026, PTC Therapeutics has withdrawn its New Drug Application (NDA) for **Translarna (ataluren)** from the U.S. FDA due to insufficient evidence of effectiveness for treating nonsense mutation Duchenne muscular dystrophy (nmDMD)[3][4]. Translarna is **not FDA-approved in the U.S.** and is unavailable through standard commercial channels or insurance coverage[2][6]. This guide outlines potential **PTC Therapeutics patient assistance programs (PAPs)**, which may provide access to investigational or expanded access supplies for eligible patients while exploring alternatives. Always verify current program status by contacting PTC directly, as availability is uncertain post-withdrawal[1][7]. ## About Translarna (Ataluren) **Translarna (ataluren)** is an oral protein restoration therapy designed to enable the formation of functioning dystrophin protein in patients with genetic disorders caused by **nonsense mutations**—genetic alterations that prematurely halt protein synthesis[3]. In **Duchenne muscular dystrophy (DMD)**, which affects about 1 in 3,500-5,000 boys, nonsense mutations account for approximately **13-15% of cases** and prevent full dystrophin production, leading to muscle weakness and progressive loss of function[4][7]. Translarna works by promoting 'read-through' of the premature stop codon in the genetic code, potentially allowing production of a truncated but partially functional dystrophin protein. It has been available in countries like the UK under conditional approval since 2014, with real-world data from the STRIDE registry showing some patients on therapy maintained ambulation and lung function longer than untreated peers[4]. However, U.S. and recent European reviews have questioned its clinical effectiveness, leading to the FDA NDA withdrawal and EMA non-renewal concerns[3][9]. **Typical dosing** (where available): 10 mg/kg in the morning, 10 mg/kg midday, and 20 mg/kg in the evening, taken with meals. It's studied for boys aged 5+ with confirmed nmDMD[5]. Common side effects include vomiting, diarrhea, and rash; monitoring for kidney function is recommended. ## Who Qualifies for PTC Patient Assistance? PTC Therapeutics offers **patient assistance programs** for eligible U.S. patients, potentially including free or low-cost Translarna through expanded access, compassionate use, or bridge programs while FDA approval is pursued (though currently withdrawn)[2][7]. Exact details are not publicly detailed post-withdrawal, but general PAP criteria for rare disease drugs like this include: - Confirmed diagnosis of **nmDMD** via genetic testing showing a nonsense mutation[5]. - Age 5 years or older[4]. - Currently ambulatory or with stable function. - No FDA-approved alternatives fully addressing needs (e.g., despite corticosteroids)[5]. - U.S. residency. **Income Eligibility**: PTC programs typically target patients at or below **400-500% of the Federal Poverty Level (FPL)**, though specifics for Translarna are unavailable[2]. Here's a general breakdown based on similar rare disease PAPs (verify with PTC): | Household Size | 400% FPL (2026 est.) | 500% FPL (2026 est.) | |---------------|----------------------|----------------------| | Individual | $60,240 | $75,300 | | Couple | $81,760 | $102,200 | | Family of 3 | $103,280 | $129,100 | | Family of 4 | $124,800 | $156,000 | *Notes*: Thresholds adjust annually; commercial insurance often required with high copays, or uninsured/underinsured qualify fully. Medicare patients may have limited PAP access[2]. ## Insurance Requirements Translarna lacks FDA approval, so it's **not covered by U.S. insurers** like Aetna, CVS Health, Medicare, or Medi-Cal[2][5]. Insurers require: - Genetic confirmation of nmDMD. - Prior authorization with specialist (neurologist) prescription. - Concurrent oral corticosteroid use (e.g., prednisone) unless contraindicated[5]. For off-label or expanded access, strong appeals in states like California (via DMHC or CDI) succeed with evidence of medical necessity, lack of alternatives, and declining function[2]. Medicare Part D does not cover unapproved drugs; explore foundation grants instead. ## Step-by-Step Application Process 1. **Confirm Eligibility**: Get genetic testing for nonsense mutation (e.g., via neuromuscular specialist). Discuss with your doctor if expanded access via PTC is possible[7]. 2. **Contact PTC Therapeutics**: Call patient services (typically 1-833-PTC-HELP or similar; verify online) or visit ptcbio.com/patient-support. Request PAP application for Translarna[2]. 3. **Gather Documents**: - Proof of diagnosis (genetic report). - Income verification (tax returns, pay stubs). - Insurance details (or proof of uninsured status). - Prescription from neurologist. - Recent labs (LVEF, FVC for stability)[5]. 4. **Submit Application**: Online, mail, or fax. Physician portal often required. 5. **Follow Up**: Expect 2-4 weeks processing; PTC may coordinate with your pharmacy. ## Timeline and Delivery - **Processing**: 1-4 weeks for initial approval[2]. - **Delivery**: Shipped free to your home or doctor's office via specialty pharmacy. Monthly refills if stable. - **Duration**: Often 1 year, with reauthorization based on function (ambulation, lung function)[5]. ## Alternatives if Denied or Unavailable - **FDA-Approved DMD Therapies**: Exon-skipping drugs (e.g., for other mutations) with prior auth; corticosteroids (prednisone, deflazacort) covered broadly[2]. - **Foundation Support**: CureDuchne, Parent Project Muscular Dystrophy grants[1][7]. - **Clinical Trials**: Check clinicaltrials.gov for ataluren studies (e.g., NCT02369731 registry)[8]. - **State Programs**: California Medi-Cal, Covered California[2]. - **International Access**: Travel considerations for approved regions (consult physician). ## Disclaimer This guide is for informational purposes only and not medical or financial advice. Translarna's U.S. status is fluid; contact PTC Therapeutics directly for latest PAP details. Consult your healthcare provider for personalized options. Eligibility and availability subject to change. Word count: 1028.

Program information last verified: March 30, 2026